APA (7th ed.) Citation

Sabatier, R., Rousseau, F., Joly, F., Cropet, C., Montégut, C., Frindte, J., . . . Ray-Coquard, I. (2023). Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial. European journal of cancer, 181, . https://doi.org/10.1016/j.ejca.2022.11.029

Chicago Style (17th ed.) Citation

Sabatier, Renaud, et al. "Efficacy and Safety of Maintenance Olaparib and Bevacizumab in Ovarian Cancer Patients Aged ≥65 Years from the PAOLA-1/ENGOT-ov25 Trial." European Journal of Cancer 181 (2023). https://doi.org/10.1016/j.ejca.2022.11.029.

MLA (9th ed.) Citation

Sabatier, Renaud, et al. "Efficacy and Safety of Maintenance Olaparib and Bevacizumab in Ovarian Cancer Patients Aged ≥65 Years from the PAOLA-1/ENGOT-ov25 Trial." European Journal of Cancer, vol. 181, 2023, https://doi.org/10.1016/j.ejca.2022.11.029.